Board of Directors

Derek Hennecke is Executive Chairman of Codis and a long-time board leader, having served as a board observer since 2010 and Chairman since 2018. He brings deep particle-engineering and pharmaceutical services experience across micronization, spray drying, and complex oral dose-form technologies, with a track record of building and scaling CDMO businesses and strengthening quality, reliability, and customer delivery. Derek’s career includes extensive leadership roles across Europe, giving him a practical, cross-border perspective on operations, regulatory expectations, and commercial execution. He holds multiple graduate degrees from Harvard University and Erasmus University in The Netherlands and applies that analytical rigor to Codis’ strategy, platform integration, and long-term value creation.

Michael Caspani has been involved with Codis and its predecessor (Particle Dynamics) since 2019. He is a Managing Director at BroadOak Capital Partners, where he focuses on making debt and equity investments in, and working with management teams of, growth stage companies across the pharma and life sciences value chain. Prior to joining BroadOak, he held investment and advisory roles at Macquarie, GCA Savvian, and The Gladstone Companies. He began his career as an investment banking analyst in the Leveraged Finance group at Banc of America Securities. Michael earned a B.S. with Special Attainments in Commerce from Washington and Lee University, and holds an M.B.A. from the Tuck School of Business at Dartmouth.

Nicolas is a seasoned executive with nearly two decades of leadership experience in the pharmaceutical industry. With deep experience in managing multi-million-dollar operations, M&A integration, and international expansion, he combines operational rigor with strategic vision to drive growth and innovation at Codis. Nicolas earned a Bachelor’s degree in Engineering and holds an MBA from the McGill/HEC Universities.

Shaun has been involved with Codis through Research Corporation Technologies (RCT), where he is President and a member of the Board of Directors. At RCT, he focuses on investment management and technology development and licensing across therapeutics, life science tools, and diagnostics. RCT’s portfolio includes numerous venture-backed companies and a number of landmark pharmaceutical platforms and products. Shaun holds a Master’s degree in International Economics from the Johns Hopkins University School of Advanced International Studies and a Bachelor’s degree in Economics and Ecology/Evolutionary Biology from the University of Arizona. He also serves on the boards of several organisations within the life sciences and research ecosystem.

Matthew is a Partner at 1315 Capital, a private equity firm exclusively focused on investing in growth-stage healthcare companies.  He has worked on over $1 billion in healthcare financings in over two decades of growth stage investing experience, with a focus on the pharma/medtech outsourcing and pharma/medtech product sectors. Prior to joining 1315 Capital, Matthew spent 9 years at HealthCare Royalty Partners, most recently as a Managing Director. He currently serves on the board of Coating Place, Codis, Experic, Medivant Healthcare, Primrose Bio, ProSciento, SciSafe, USpharma, and previously served on the board of Reaction Biology (acquired by Cobepa) and Verogen (acquired by QIAGEN). Matthew also serves on the Board of Directors of Life Sciences Pennsylvania.

Matthew received a BSc in Engineering, magna cum laude, from Princeton University, an MBA with honors from The Wharton School of the University of Pennsylvania, and a Master of Biotechnology degree from the University of Pennsylvania